A four-week supply of the 7.5-milligram and 10-milligram single-dose vials are $499 at first fill and refills within 45 days, and then $599 and $699, respectively.
The presentation differs from Zepbound’s single-dose autoinjector pens, since the vials require patients to use a syringe to draw up the medicine and self-inject. All doses — 2.5-, 5-, 7.5-, 10-, 12.5- and 15-milligram — are available as autoinjector pens.
The drugmaker also reduced the prices of the 2.5-milligram and 5-milligram presentations by about $50 each. In late August, the doses cost $399 and $549, respectively. They are now sold for $349 and $499 per month supply, Eli Lilly said Feb. 25.
Eli Lilly is debuting the discounted single-dose vials through LillyDirect, its direct-to-consumer platform that launched in January 2024. The company said the new offering will enhance price transparency and reach more patients; LillyDirect bypasses third-party drug suppliers and offers the discounted prices regardless of insurance coverage.
A four-week supply of Zepbound (tirzepatide) costs about $1,000.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
